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Introduction
Influenza A is a serious disease causing recurring outbreaks with significant negative effects on the general health status globally as well as on the economy of affected populations.
In April of 2009 a novel strain of (H1N1) swine-origin influenza A was reported in Mexico and the United States. [1] [2] [3] The rapid spread of this virus to over 70 countries of the world urged the WHO to raise its pandemic alert level to the highest phase 6 by June 11, 2009 . This new A(H1N1)pdm09 virus was found to be a triple reassortant containing a combination of gene segments of swine, human and avian origin. [4] [5] [6] The 2009 pandemic influenza A turned out to be relatively mild in its symptoms when compared to other strains responsible for previous pandemics. Most individuals infected with the 2009 pandemic H1N1 strain usually developed uncomplicated illness with full recovery within a week. However, this may be a transient situation because influenza viruses are constantly undergoing changes, both by antigenic drift (mutations due to the error-prone genomic RNA amplification) as well as by antigenic shift (exchange of genomic segments during co-infection by two different strains). The best example of these phenomena was the 1918 Spanish flu pandemic virus. The initial outbreak was relatively mild in terms of clinical impact, but had acquired higher virulence when it returned in the next season. Changes are in some cases gradual and more predictable. Despite this fact the rate of genome mutation is high enough to cause the replacement of circulating strains every 3-5 years with variants that underwent antigenic changes sufficient for substantial or complete evasion of existing antibody response. Therefore, it is crucial to monitor, not only the mutations leading to resistance against antiviral drugs, but also those that modify the most important viral epitopes. The latter lead to gradual weakening of the antigen-antibody interactions and therefore reduce the efficacy of existing vaccine.
The viral surface protein hemagglutinin (HA) is the primary target for neutralizing antibodies in natural infections. 7 The antigenic variation of HA is the main mechanism (Fig. 2) , and nine were unique to single isolates. It seems unlikely that mutations arose during the short passages of the original virus from swabs in MDCK cells.
DNA codons containing detected point mutations were translated to amino acids and compared with the pandemic reference sequence. Furthermore, their physico-chemical properties and localization within HA protein structure were also determined. All detected point mutations as well as corresponding changes of amino acids, in comparison to reference sequence, are summarized in Table 2 . Two mutations (TAC>AAC, GTA>ATA) close to the vicinity of 3' end of the amplicones, were not analyzed as they were localized within the primer binding region. Five mutations were synonymous substitutions (Table 2) , that did not affect the HA protein sequence. In three cases the mutations led to substitutions preserving the physico-chemical properties of the encoded amino acids. However, some of the nonsynonymous substitutions affected the physico-chemical properties of amino acids ( Table 2) . The mutated fragments listed in Table 2 were compared with available HA sequences of Taiwan pandemic influenza isolates deposited in the NCBI and EpiFlu data banks. The phylogenetic tree constructed for the 935 nt HA gene fragment, showed that the isolates may be divided into several clusters (Fig. 4) . The isolates described in this work form a distinguishable cluster except isolate 2010-01164 which shares the V47G mutation with a group represented by isolate EPI382342. It should be pointed out that the A48D and E66K mutations identified here were not found in any other group of isolates that were subjected to comparative analysis. They may therefore represent novel changes in HA which appeared in Hemagglutinin is a homo-trimer with each of the subunits comprising two polypeptides: HA1 and HA2. They fold into an α-helical stem and a globular domain, both of which can interact with the host cell membrane. Also neutralizing antibodies can bind to the both structures, as seen in crystallographic studies e.g, 3ZTN or 1EO8, but primarily they target the globular domain, where the HA receptor binding site is also located. we used data for H3 hemagglutinin from the 1QFU complex and matched its structure with that of H1 hemagglutinin (3ZTN) to predict their interaction interface. The HA-Ab interface with the BH151 antibody is formed by 14 residues (50-54, 65-70 and 81-85 of HA1). The E66K mutation (Fig. 3) is within this interface and could affect it as it changes both the charge and size of the amino acid. Single mutations within HA-AB interface, or even those located in its close vicinity, have already been shown to allow viruses to escape neutralization. 18 Mutations of the interface residue D54 to N or to Y make the influenza virus immune to the HC45 and BH151 antibodies. 19, 20 This effect may be caused by introducing a new glycosylation site. 21 It is noteworthy that the mutation E66K may create a new glycosylation site and residue 66 is in close contact with D54, forming a hydrogen bond with its main chain in the crystal structure 1EO8.
On the other hand, although mutations at a protein-protein interface may be a strong indication of structural hindrances hampering complex formation, there are also studies showing the ability of antibodies to bind protein variants with one or a few amino acids changed. 20, 22 The close proximity to a known escape mutation residue, exposure and interface location suggest the major role of residue 66 in modulating HA-Ab affinity. Nevertheless, this hypothesis needs further studies.
It is also worth mentioning that the observed substitutions present in epitope E of H1 may affect vaccine effectiveness when they become widespread. The vaccine effectiveness undergoes annual changes, partially due to antigenic distances between the recommended vaccine strain and the circulating strain. 13 One of factors to quantify such antigenic distance is peptope value which describes the highest fraction of substituted amino acids in all epitopes. 23, 24 Recent studies showed that vaccine effectiveness correlates with the pepitope value, thus one can quantify the impact of substituted amino acids on the predicted level of vaccine effectiveness for influenza-like illnesses, which is 52.7%. Table 1 .
Total RNA extraction and cDNA synthesis
Viral RNA was extracted from cultured viral isolates using QIAamp Viral RNA Mini Kits (Qiagen, cat. no. 52904). In brief, 140 µl of a clinical specimen was mixed with AVL buffer, followed by 560 µl of ethanol. The resultant suspensions were applied on a QIAamp Mini column for RNA binding. After washing with wash buffers and eluting with TE buffer, the eluted viral RNA was used in the reverse transcription assay. Alternatively, automated extraction was conducted using a MagNa Pure LC extraction system (Roche). For cDNA preparation, BluePrint(TM) 1st Strand cDNA Synthesis Kit (Takara BIO Inc, cat. no. 6110) was used. Template viral RNA and random primers were mixed in a total volume of 10 µl.
After incubating at 65°C for 5 minutes followed by cooling on ice, reaction buffer, reverse transcriptase and water were added. The resultant mixture was incubated at 30°C for 10 
MSSCP-based minor genetic variants enrichment procedure
The PCR products were analyzed by the MSSCP method at strictly controlled (± 0.2ºC) gel temperature in a dedicated apparatus: DNAPointer® System/BioVectis (Warsaw, Poland) as described by Kaczanowski et al. 25 Briefly, the PCR products were heat denatured and ssDNA conformers were resolved on a 9% polyacrylamide gel in native conditions (TBE buffer), the gel temperature decreasing during the run from the initial 15°C to 10°C to 5°C. 
Calculation of pepitope value and vaccine effectiveness
All calculations were based on data shown in Pan et al. 24 The P-value which is used to measure antigenic distance between circulating and vaccine strain 21 was calculated for every epitope of H1 (A-E) using equation 8 in reference [24] :
P-value= Number of substitutions in the epitope / Number of amino acids in the epitope.
The calculation was based on the assumption that the only difference between the hypothetical strain and vaccine strain are the five amino acid substitutions present in epitope E of H1. The Pepitope value is the highest of all P-values 24 . The P-value for epitope E was taken as the pepitope value for further calculations. As shown in chart on Figure 2 in reference [24] based on epidemiological data for various circulating and vaccine strains from 1982 to 2008 taken from Table II in 
